SCHEMBL4200838

SCHEMBL4200838

O=C(c1ccc(Br)cc1)C1CCNC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
CYP2D6 P10635 1/20 0.54
KMT2A Q03164 1/20 0.54
MGLL Q99685 2/20 0.46
HSD11B1 P28845 2/20 0.46
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
SLC18A3 Q16572 2/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
MELK Q14680 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CCR5 P51681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL26187206 0.98 MEN1 (0.57) MEN1CYP2D6KMT2AMGLLHSD11B1
SCHEMBL1135130 0.89 MEN1 (0.67) MEN1CYP2D6KMT2AMGLLHSD11B1
Bromide SCHEMBL10966041 0.88 MEN1 (0.65) MEN1CYP2D6KMT2AMGLLHSD11B1
Hydrochloric Acid SCHEMBL11518027 0.88 MEN1 (0.70) MEN1CYP2D6KMT2AMGLLHSD11B1
SCHEMBL4192969 0.85 CES2 (0.46) MEN1CYP2D6KMT2AMGLLHSD11B1
Hydrochloric Acid SCHEMBL28507556 0.84 MEN1 (0.46) MEN1CYP2D6KMT2AMGLLHSD11B1
SCHEMBL2146518 0.83 MEN1 (0.54) MEN1CYP2D6KMT2AMGLLHSD11B1
SCHEMBL407286 0.82 KMT2A (0.53) MEN1CYP2D6KMT2AMGLLHSD11B1
Hydrochloric Acid SCHEMBL5478246 0.81 MEN1 (0.57) MEN1CYP2D6KMT2AMGLLHSD11B1
Hydrochloric Acid SCHEMBL5478248 0.81 MEN1 (0.57) MEN1CYP2D6KMT2AMGLLHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368619-A1 SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2025-12-04 US disclosed
US-20250250261-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2025-08-07 US disclosed
EP-4584257-A1 SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-07-16 EP disclosed
CN-119836419-A Substituted tetrahydrocyclohepta [ E ] indole derivatives, method for the production and therapeutic use thereof 赛诺菲 2025-04-15 CN disclosed
EP-4508032-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
CN-119032079-A Novel substituted fluorinated vinyl-N-propyl-pyrrolidine compounds, process for their preparation and their therapeutic use 赛诺菲 2024-11-26 CN disclosed
WO-2024052518-A1 SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2024-03-14 WO disclosed
WO-2023198905-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
WO-2023198879-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
WO-2023198879-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
WO-2023198905-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
CN-112243439-A Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2021-01-19 CN disclosed
US-20120302547-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2012-11-29 US disclosed
US-8263772-B2 MCH receptor antagonists ELI LILLY AND COMPANY (US) 2012-09-11 US disclosed
US-20090093456-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-04-09 US disclosed
EP-2029609-A2 NOVEL MCH RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2009-03-04 EP disclosed
WO-2007146758-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302547-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R MEN1 545/4885CYP2D6 1210/4885KMT2A 997/4885
US-20250368619-A1 SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF CYP19A1, NR5A1, FSHR MEN1 2744/4885CYP2D6 205/4885KMT2A 2143/4885
US-20250250261-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF FSHR, GPER1, ESRRA MEN1 979/4885CYP2D6 725/4885KMT2A 3023/4885
US-20090093456-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R MEN1 606/4885CYP2D6 1171/4885KMT2A 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.